Alectinib cleared in Japan
Ministry of Health, Labor and Welfare approves Roche's ( OTCQX:RHHBY
) alectinib for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The product will be available for sale later this year. In June 2013, ...
Read the rest of this article on SeekingAlpha.com: SA Currents